(Press-News.org) New research published in NEJM and presented at this year’s Annual Meeting of the European Association for the Study of Diabetes (EASD) in Madrid (9-13 Sept) shows that a new class of insulin that is injected once a week is as effective as daily insulin injections for effective and safe blood sugar management in patients with type 2 diabetes. The study is by Dr Carol Wysham, MultiCare Rockwood Center for Diabetes and Endocrinology, Spokane, WA, USA, and colleagues.
When patients with type 2 diabetes find their oral medications alone can no longer control their blood sugar, insulin therapy is added and injection frequency (having daily injections) is among the main factors that can contribute to failures in treatment adherence (others include worry about weight gain and having hypoglycaemic episodes or ‘hypos’).
Insulin efsitora alfa (efsitora) is a new basal insulin designed for once-weekly administration. Clinical data to date on safety and efficacy have been limited to small phase 1 or phase 2 trials. In this new phase 3 study, the efficacy of once-weekly efsitora was compared to daily injections of insulin degludec (a standard insulin) in adult patients that had not yet begun insulin therapy (on multiple oral diabetes medications but still were not at their glycaemic goals).
The authors conducted a 52-week study in which participants were randomly assigned in a 1:1 ratio to receive efsitora or degludec. The primary end point was the change in the glycated haemoglobin (HbA1c – a measure of blood sugar control) level from baseline to week 52; they hypothesised that efsitora would be noninferior to degludec (non-inferiority margin, 0.4%). Secondary and safety end points included the change in the glycated haemoglobin level in subgroups of participants using and not using the relatively new glucagon-like peptide-1 (GLP-1) receptor agonist antidiabetic medications, the percentage of time that the glucose level was in the target range of 70 to 180 mg per decilitre in weeks 48 through 52, and hypoglycaemic episodes.
A total of 928 participants were randomly assigned to efsitora (466) or degludec (462). The mean glycated hemoglobin level decreased from 8.21% at baseline to 6.97% (absolute change 1.26%) at week 52 with efsitora and from 8.24% to 7.05% (absolute change -1.17%) with degludec; a treatment difference of 0.09% that demonstrated non-inferior reduction of Hb1Ac between efsitora and degludec.
Efsitora was also noninferior to degludec with respect to the change in the glycated haemoglobin level in participants using and not using GLP-1 receptor agonists. The percentage of time that the glucose level was within the target range was 64.3% with efsitora and 61.2% with degludec (estimated treatment difference, 3.1 percentage points; statistically significant). The rate of combined clinically significant or severe hypoglycaemia was 0.58 events per participant-year of exposure with efsitora and 0.45 events per participant-year of exposure with degludec, but this finding was not statistically significant. No severe hypoglycaemia was reported with efsitora; six episodes were reported with degludec. The incidence of adverse events was similar in the two groups.
The authors say: “In adults with type 2 diabetes who had not previously received insulin, once-weekly efsitora was noninferior to once-daily degludec in controlling high blood sugar by reducing glycated haemoglobin levels.”
They add: “A once-weekly insulin has the potential to simplify dose administration and diminish barriers to starting insulin therapy by means of a reduction in injection burden as compared with a once-daily insulin. A recent study evaluating preferences for a once-weekly basal insulin in adults with type 2 diabetes indicated that both patients and providers would prefer once-weekly basal insulin over current basal insulin preparations.”
On GLP-1 agonists, they add: “Given treatment guidelines and recommendations to incorporate GLP-1 receptor agonists earlier in treatment, along with their growing use worldwide, it is relevant to show that efsitora can be effectively and safely added to such therapy. Here, efsitora showed noninferiority to degludec with respect to the change in the glycated haemoglobin level among participants using and not using GLP-1 receptor agonists, without substantial treatment differences in hypoglycaemia between subgroups.”
END
New research shows new class of once-weekly insulin as effective as daily injections for patients with type 2 diabetes
2024-09-10
ELSE PRESS RELEASES FROM THIS DATE:
New class of weekly insulin as effective as daily injections for managing blood sugar in patients with type 1 diabetes; but higher rates of hypoglycaemia means vigilance needed (QWINT-5)
2024-09-10
New research published in The Lancet and presented at this year’s Annual Meeting of the European Association for the Study of Diabetes (EASD) in Madrid (9-13 Sept) shows that a new class of insulin that only needs to be injected once weekly is as effective as daily insulin injections for effective blood sugar management in patients with type 1 diabetes. However, higher rates of hypoglycaemia using the new class means vigilance is needed for dose initiation and optimisation. The study is by Dr Richard M Bergenstal, ...
Like father, like daughter
2024-09-10
RIVERSIDE, Calif. -- When they become fathers, men who have an unhealthy, high-cholesterol diet can cause increased risk of cardiovascular disease, or CVD, in their daughters, a University of California, Riverside-led mouse study has found.
The research, published in the journal JCI Insight, is the first to demonstrate this result seen only in female offspring.
CVD, the leading cause of death globally, is a group of disorders that affects the heart and blood vessels. Hypertension (high blood pressure) is a leading risk factor ...
2-bromopalmitate reduces senescence in human cells: Role of palmitoylation
2024-09-10
“For the first time, the present study revealed a critical role for protein palmitoylation in the development of a DNA damage-induced senescence phenotype.”
BUFFALO, NY- September 10, 2024 – A new research paper was published in Aging (listed by MEDLINE/PubMed as "Aging (Albany NY)" and "Aging-US" by Web of Science), Volume 16, Issue 16 on August 23, 2024, entitled, “2-Bromopalmitate treatment attenuates senescence phenotype in human adult cells - possible role of palmitoylation.”
As ...
Don’t judge a fossil by its teeth: despite its toothy beak, this ancient bird ate fruit, not fish
2024-09-10
For paleontologists who study animals that lived long ago, fossilized remains tell only part of the story of an animal’s life. While a well-preserved skeleton can provide hints at what an ancient animal ate or how it moved, irrefutable proof of these behaviors is hard to come by. But sometimes, scientists luck out with extraordinary fossils that preserve something beyond the animal’s body. Case in point: in a new study published in the journal Current Biology, researchers found fossilized seeds in the stomachs of one of the earliest birds. This discovery shows that these birds were eating ...
A new screening tool to improve telehealth access and equity
2024-09-10
In a new study published in JAMA Network Open, researchers at Thomas Jefferson University have developed a novel screening tool to measure digital health readiness, which will be critical in addressing barriers to telehealth adoption among diverse patient populations.
The COVID-19 pandemic facilitated many rapid changes in healthcare, including a shift to using telehealth services across the U.S. instead of traditional in-person doctor’s visits. This ensured that patients continued to receive vital care, while only needing access to a mobile device or computer with a webcam. But just because a ...
New law regulating out-of-pocket drug spending saves cancer patients more than $7,000 a year, study finds
2024-09-10
For more information, contact:
Nicole Fawcett, nfawcett@umich.edu
EMBARGOED for release at 11 a.m. Sept. 10, 2024
New law regulating out-of-pocket drug spending saves cancer patients more than $7,000 a year, study finds
The Inflation Reduction Act’s limit on Medicare Part D spending leads to significant savings for patients prescribed oral chemotherapy
ANN ARBOR, Michigan — As prescription oral chemotherapies have become a common form of cancer treatment, some patients were paying more than $10,000 a year for medications. A new study ...
Estimated health and economic outcomes of racial and ethnic tuberculosis disparities in US-born persons
2024-09-10
About The Study: In this modeling study of racial and ethnic disparities of tuberculosis (TB), these disparities were associated with substantial future health and economic outcomes of TB among U.S.-born persons without interventions beyond current efforts. Actions to eliminate disparities may reduce the excess TB burden among these persons and may contribute to accelerating TB elimination within the U.S.
Corresponding Author: To contact the corresponding author, Nicole A. Swartwood, MSPH, email nswartwood@hsph.harvard.edu.
To ...
Genetic analysis sheds light on the role of IFT140 in polycystic kidney disease
2024-09-10
Tokyo Medical and Dental University (TMDU) researchers uncover the genetic link in patients with polycystic kidney disease lacking family history
Tokyo, Japan – Polycystic kidney disease (PKD) is an intractable disorder that causes fluid-filled cysts to grow in the kidneys. It is typically seen in adults. As one of the most prevalent hereditary kidney diseases, the autosomal dominant form of PKD is usually caused by mutations in the PKD1 and PKD2 genes. However, one out of ten patients with this condition typically exhibit no family history of the disease and lack ...
Scientists use AI to detect chronic high blood pressure in people’s voice recordings
2024-09-10
NEW YORK/TORONTO – September 10, 2024 – Researchers at Klick Labs unveiled a cutting-edge, non-invasive technique that can predict chronic high blood pressure (hypertension) with a high degree of accuracy using just a person's voice. Just published in the peer-reviewed journal IEEE Access, the findings hold tremendous potential for advancing early detection of chronic high blood pressure and showcase yet another novel way to harness vocal biomarkers for better health outcomes.
The ...
NIH Kids First Program announces the release of three new pediatric research datasets exploring childhood rare disease
2024-09-10
WHO: The Gabriella Miller Kids First Pediatric Research Program (Kids First), an initiative of the National Institutes of Health (NIH)
WHAT: Kids First announces the release of three comprehensive new pediatric research datasets exploring childhood cancers and congenital disorders. New publicly available datasets include:
CHILDHOOD CANCERS
Gabriella Miller Kids First (GMKF) Pediatric Research Program in Susceptibility to Ewing Sarcoma Based on Germline Risk and Familial History of Cancer.
Principal Investigators: Joshua D. Schiffman, MD. Huntsman Cancer Institute, ...